Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Systematic review of combinations of targeted or immunotherapy in advanced solid tumors
Aaron C. Tan, Stephen Bagley, Patrick Y. Wen, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 7, pp. e002459-e002459
Open Access | Times Cited: 63

Showing 1-25 of 63 citing articles:

The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
Karin E. de Visser, Johanna A. Joyce
Cancer Cell (2023) Vol. 41, Iss. 3, pp. 374-403
Open Access | Times Cited: 1595
Clinical cancer immunotherapy: Current progress and prospects
Chenglong Liu, Mengxuan Yang, Daizhou Zhang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 155
The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
Deniz Can Güven, Taha Koray Şahin, Enes Erul, et al.
Frontiers in Molecular Biosciences (2022) Vol. 9
Open Access | Times Cited: 135
Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement
Stephen Bagley, Shawn Kothari, Rifaquat Rahman, et al.
Clinical Cancer Research (2021) Vol. 28, Iss. 4, pp. 594-602
Open Access | Times Cited: 119
Circular RNA cancer vaccines drive immunity in hard-to-treat malignancies
Hongjian Li, Kun Peng, Kai Yang, et al.
Theranostics (2022) Vol. 12, Iss. 14, pp. 6422-6436
Open Access | Times Cited: 119
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial
Jason J. Luke, Manish R. Patel, George R. Blumenschein, et al.
Nature Medicine (2023) Vol. 29, Iss. 11, pp. 2814-2824
Open Access | Times Cited: 55
Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies
Nating Xiong, Heming Wu, Zhikang Yu
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 22
Current Molecular Combination Therapies Used for the Treatment of Breast Cancer
Yiling Wang, Audrey Minden
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 19, pp. 11046-11046
Open Access | Times Cited: 66
Hydrogen Sulfide Creates a Favorable Immune Microenvironment for Colon Cancer
Taohua Yue, Jichang Li, Jing Zhu, et al.
Cancer Research (2022) Vol. 83, Iss. 4, pp. 595-612
Open Access | Times Cited: 57
Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond
Samar Al Bitar, Marwan El‐Sabban, Samer Doughan, et al.
World Journal of Gastroenterology (2023) Vol. 29, Iss. 9, pp. 1395-1426
Open Access | Times Cited: 37
Targeting PI3K/AKT/mTOR Signaling to Overcome Drug Resistance in Cancer
Muhammad Tufail, Wendong Wan, Canhua Jiang, et al.
Chemico-Biological Interactions (2024) Vol. 396, pp. 111055-111055
Closed Access | Times Cited: 11
Gut microbiota influences the efficiency of immune checkpoint inhibitors by modulating the immune system (Review)
Haihong Jiang, Qinlu Zhang
Oncology Letters (2024) Vol. 27, Iss. 2
Open Access | Times Cited: 9
Viral expression of NE/PPE enhances anti-colorectal cancer efficacy of oncolytic adenovirus by promoting TAM M1 polarization to reverse insufficient effector memory/effector CD8+ T cell infiltration
Shuo Wang, Lingkai Kong, Linpei Wang, et al.
Journal of Experimental & Clinical Cancer Research (2025) Vol. 44, Iss. 1
Open Access | Times Cited: 1
Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer
Ting-Lin Yang, Wenhui Li, Tao Huang, et al.
Journal of Personalized Medicine (2023) Vol. 13, Iss. 3, pp. 526-526
Open Access | Times Cited: 18
PD‐1 inhibition with retifanlimab and/or arginase inhibition with INCB001158 in Japanese patients with solid tumors: A phase I study
Yasutoshi Kuboki, Takafumi Koyama, Nobuaki Matsubara, et al.
Cancer Medicine (2024) Vol. 13, Iss. 8
Open Access | Times Cited: 6
Strategies for Heating Up Cold Tumors to Boost Immunotherapies
Daniel J. Zabransky, Mark Yarchoan, Elizabeth M. Jaffee
Annual Review of Cancer Biology (2023) Vol. 7, Iss. 1, pp. 149-170
Closed Access | Times Cited: 16
Blocking CD47-SIRPα Signal Axis as Promising Immunotherapy in Ovarian Cancer
Xukai Luo, Yini Shen, Wu Huang, et al.
Cancer Control (2023) Vol. 30
Open Access | Times Cited: 15
Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification
Arielle Elkrief, Igor Odintsov, Vladimir Markov, et al.
Journal of Thoracic Oncology (2023) Vol. 18, Iss. 9, pp. 1165-1183
Closed Access | Times Cited: 11
Next-Generation Adjuvants: Applying Engineering Methods to Create and Evaluate Novel Immunological Responses
Jeremiah Kim, Matthew G. Rosenberger, Nakisha S. Rutledge, et al.
Pharmaceutics (2023) Vol. 15, Iss. 6, pp. 1687-1687
Open Access | Times Cited: 11
The Role of Short-Chain Fatty Acids, Particularly Butyrate, in Oncological Immunotherapy with Checkpoint Inhibitors: The Effectiveness of Complementary Treatment with Clostridium butyricum 588
Massimiliano Cazzaniga, Marco Cardinali, Francesco Di Pierro, et al.
Microorganisms (2024) Vol. 12, Iss. 6, pp. 1235-1235
Open Access | Times Cited: 4
Lactate and Lactylation: Dual Regulators of T-Cell-Mediated Tumor Immunity and Immunotherapy
Zi-Rui Hao, Xiaoping Tan, Qing Zhang, et al.
Biomolecules (2024) Vol. 14, Iss. 12, pp. 1646-1646
Open Access | Times Cited: 4
Advancing personalized cancer therapy: Onko_DrugCombScreen—a novel Shiny app for precision drug combination screening
Jingyu Yang, Meng Wang, Jürgen Dönitz, et al.
NAR Genomics and Bioinformatics (2025) Vol. 7, Iss. 1
Open Access
Cancer Immunotherapy
Javad Arabpour, Fatemeh Davodabadi, Manisha Nigam
(2025), pp. 49-113
Closed Access
First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone for advanced esophageal cancer: a cost-effectiveness analysis
Xueqiong Cao, Hongfu Cai, Na Li, et al.
Therapeutic Advances in Medical Oncology (2022) Vol. 14
Open Access | Times Cited: 15
Structure based virtual screening and molecular simulation study of FDA-approved drugs to inhibit human HDAC6 and VISTA as dual cancer immunotherapy
Muhammad Shahab, Haitham Al‐Madhagi, Guojun Zheng, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top